Phase III and large retrospective analyses consistently report a significant reduction in incidence of symptomatic cardiotoxicity with PLD, yet survival benefits remain modest and toxicity simply shifts toward mucocutaneous adverse effects such as palmarplantar erythrodysesthesia and stomatitis [212]
Without RCT data on semaglutide for the management of BAD, it is difficult to evaluate its safety and efficacy compared with other BAD therapeutics, but the abovementioned case underscores that newer, longer-acting, and more potent GLP-1RAs not necessarily provide better treatment results in BAD as compared with older, shorter-acting, and less potent GLP-1RAs such as liraglutide
J.MirandaM.RomeroF
What Tesamorelin Does: Increases endogenous growth hormone Reduces visceral adipose tissue (VAT) Improves waist circumference Supports IGF-1 balance May improve liver fat markers Tesamorelin has been studied extensively in HIV-associated lipodystrophy, where it significantly reduced visceral fat without the same degree of subcutaneous fat loss
The evidence, however, is not strong enough to draw causal inference
Foods that trigger semaglutide burping Diet is the single most controllable factor in semaglutide-related burping